SILENCE CANCER ONCE AND FOR ALL

BLOCK THE GENES THAT CAUSE CANCER

WE WANT TO HEAR FROM YOU

FOR MORE INFORMATION ON OUR NEWLY DISCOVERED TARGETED CANCER CELL THERAPY

OUR COMPANY

Targeted Oncogene Silencing Technology for Cancer

KOP Therapeutics is a biotechnology company, in partnership with Thomas Jefferson UniversitySidney Kimmel Cancer Center, focused on the validation and commercialization of its newly discovered genomic drug platform.

FIND OUT MORE

Team

Principal Investigators
KOP Scientific Advisory Board

Partnering with world experts in cancer biology

KOP is partnering with Thomas Jefferson University to develop new cancer therapies trough an exclusive global technology license agreement. The work is led by Drs. Thakur and Wickstrom, who have been working together for over two decades on cancer genes activity imaging and therapy. Collectively, they have published 700+ peer-reviewed papers, patents, reviews and chapters and 6 books on molecular design, nucleic acid structure, gene function, mRNA translation, protein structue, and cell bioloy.
Dr. Mathew L Thakur

Professor of Radiology,
Radiation Oncology & Urology,
Thomas Jefferson University
View More

Dr. Eric Wickstrom

Professor of Biochemistry &
Molecular Biology,
Thomas Jefferson University
View More

Corporate

Tibor Gajdics

President, CEO & Chairman
KOP Therapeutics
View More

Mark Redcliffe

VP & Director
KOP Therapeutics
View More

Marco Strub

Director
KOP Therapeutics
View More

Joyce Heinzerling Davis

Director
KOP Therapeutics
View More

Advisory Board

Dr. Emma S. Guns

KOP Therapeutics
Advisory Board Member
Scientific Advisor
View More

Jeff Howlett, BSc(Econ.)

KOP Therapeutics
Advisory Board Member
Head of Research
View More

Legal

Charitable Giving

DISCOVER THE POWER OF PHILANTHROPY AND SUPPORT OUR RESEARCH WITH THOMAS JEFFERSON UNIVERSITY — SIDNEY KIMMEL CANCER CENTRE

“KOP Therapeutics’ strategic alliance and partnership with TJU & SKCC redefines tomorrow’s cancer care with world renowned scientific experts, Dr. Mathew Thakur and Dr. Eric Wickstrom revolutionary scientific breakthroughs further developed into novel therapies. Your transformational gift goes directly to Thomas Jefferson University and applied to Dr. Thakur and Dr. Wickstrom Research Fund.

Learn More

Contact Us

To learn more about the KOP Therapeutics Drug Platform, please complete this form and get involved in an extraordinary opportunity and scientific discovery.

KOP Therapeutics Corp.
Suite 404-815 Hornby Street
Vancouver, BC  Canada
V6Z 2E6

DISCLAIMER

The information contained in this presentation is in summary form only, is not intended to be complete and may contain inadvertent or unintentional errors. No representation, warranty or guarantee, expressed or implied, is made as to the fairness, accuracy or completeness of information contained herein, including the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, results or statements in relation to future matters contained in this presentation. This presentation does not constitute an offer to sell or the solicitation of an offer to buy any security and is not intended to be relied upon as advice to investors or potential investors. KOP is not liable to any recipient or third party for the use of or reliance on the information contained in this presentation.

This communication contains forward-looking statements, which relate to future events  or future performance, that are neither promises nor guarantees and are subject to numerous risks and uncertainties that may cause future results to differ materially from those expected and does not constitute an offer to sell or a solicitation of an offer to buy any securities. KOP’s securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), or any state securities laws and may not be offered or sold within the United States or to or for the account or benefit of a U.S. person (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws or an exemption from such registration is available.

Also, this communication is intended for the sole use of the addressee(s) and may contain confidential, personal and/or privileged information. Unless you are the intended, recipient, we ask that you do not retain, disclose, distribute, or take action relying on any information contained herein, and that you please alert us immediately of the erroneous delivery by return e-mail. Any communication received in error, or subsequent reply should be deleted or destroyed. Thank you for your cooperation.

COPYRIGHT AND TRADEMARK

The information in this presentation ( including certain names, graphics, logos, icons, designs, words, titles or phrases) is protected by copyright and other laws and may not be copied, reproduced, modified, uploaded, posted, transmitted, or distributed in any way without KOP’ s prior written approval. Any unauthorized downloading, re-transmission, re-publication or other copying or modification of trademarks and/or the contents herein is strictly prohibited
logo
KOP Therapeutics, 404-815 Hornby Street, Vancouver, BC Canada V6Z 2EL